Rezo Therapeutics
Full-time · San Francisco, United States
About Rezo Therapeutics Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it.
Our Founders and members of the Board are a group of esteemed, world-class scientists from the University of California, San Francisco: Nevan Krogan, Kevan Shokat, Sourav Bandyopadhyay, Natalia Jura, as well as renowned biotech executives George Scangos and Norbert Bischofberger. These leaders bring with them a strong track record of amazing discoveries and scientific breakthroughs, leading to very successful companies and many FDA approved drugs.
Capitalizing on our Series A of $78M from top-tier investors, we are leveraging a unique integrated approach, combining capabilities in genetics, proteomics, structural biology and AI to generate deep biological insights and novel therapeutic approaches.
Located in San Francisco’s vibrant Mission Bay neighborhood, Rezo is in close proximity to UCSF, numerous urban amenities, and outdoor recreational opportunities. We recognize that realizing our mission depends as much on our people as it does on our science and are building a workplace that fosters collaboration, respect, and diversity where contributing to your team’s success is valued as highly as individual achievements. If you’re passionate about team science and breaking down barriers to progress in drug development, please consider joining us!
If you do not see a job listing that matches your specific background, please apply to this posting as we will be looking for exceptional individuals in the following areas:
Proteomics
Genetics
Chemical Biology and Protein Sciences
Cancer Biology
Computational Biology, Data Science
This job is not in any teams
Rezo Therapeutics
Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it.